Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin
Open Access
- 22 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (10), 2204-2211
- https://doi.org/10.1093/jac/dkq272
Abstract
To evaluate the changes in liver stiffness measurement (LSM) in patients infected by hepatitis C virus (HCV) under pegylated interferon (Peg-IFN) plus ribavirin therapy. One hundred and forty-three HCV-infected patients, of whom 97 (68%) were also carrying HIV, who started treatment with Peg-IFN/ribavirin were included in this prospective cohort study. The outcome variable of the study was the change in LSM between baseline and the scheduled date for evaluating sustained virological response (SVR). The median (Q1–Q3) LSM values at baseline and at the SVR assessment date were 8.1 (6.2–11.6) kPa and 6.8 (5.2–9.8) kPa (P < 0.001), respectively. The median (Q1–Q3) decrease between both timepoints was −1 (−2.75, 0.3) kPa. The baseline LSM decreased ≥20% in 37 (46%) patients with SVR and in 19 (30%) without SVR (P = 0.05). In the linear regression analysis, baseline LSM {beta [standard error (SE)] −0.712 (0.044), P = 0.004}, alcohol intake ≥50 g/day [beta (SE) 0.202 (0.030), P = 0.014] and achievement of SVR [beta (SE) −0.238 (0.026), P = 0.029] were independently associated with changes in LSM. LSM decreases significantly among patients with chronic HCV infection who achieve SVR with Peg-IFN/ribavirin. These patients show a higher frequency of LSM reduction ≥20% at the date of SVR evaluation.This publication has 19 references indexed in Scilit:
- Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virusJournal of Hepatology, 2009
- Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective StudyThe American Journal of Gastroenterology, 2009
- Diagnosis, management, and treatment of hepatitis C: An updateJournal of Hepatology, 2008
- Non-invasive evaluation of liver fibrosis using transient elastographyJournal of Hepatology, 2008
- Changing trends in hepatitis C-related mortality in the United States, 1995-2004Journal of Hepatology, 2007
- Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced FibrosisAnnals of Internal Medicine, 2007
- HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosisJournal of Hepatology, 2005
- Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient dataJournal of Hepatology, 2004
- Sampling variability of liver fibrosis in chronic hepatitis CJournal of Hepatology, 2003
- Upper Gastrointestinal Tract Safety Profile of AlendronateArchives of Internal Medicine, 2000